Every 10-Q that Janux Therapeutics, Inc. (JANX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow JANX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JANX filings page.
Janux Therapeutics, Inc. reported Q2 2026 results highlighted by collaboration revenue of approximately $10.3 million from its Bristol-Myers Squibb agreement and a net loss of about $22.0 million, compared with a $33.9 million net loss a year earlier.
For the first half of 2026, collaboration revenue was $14.0 million and the net loss was $46.3 million. Operating expenses were about $42.0 million in the quarter, mainly for research and development and general and administrative activities, while interest income contributed $9.7 million.
Janux ended June 30, 2026 with $27.8 million in cash and cash equivalents, $943.1 million in short-term investments, and total assets of roughly $1.01 billion. The company is advancing multiple clinical programs, including PSMA-targeted TRACTr and TRACIr candidates and its CD19-ARM program for autoimmune diseases. Management believes existing capital will fund operations for at least 12 months while it continues to incur substantial research and development spending and operating losses.
Janux Therapeutics reported a Q1 2026 net loss of $24.4 million, or $0.39 per share, as it continued investing heavily in R&D. The company generated its first collaboration revenue of $3.7 million, driven by a new agreement with Bristol-Myers Squibb.
Janux ended the quarter with $52.6 million in cash and cash equivalents and $904.6 million in short-term investments, supporting management’s view that funding is sufficient for at least 12 months. A $15.0 million upfront payment and a $35.0 million development milestone from BMS, plus $53.6 million of remaining performance obligations, provide significant non-dilutive financing for its clinical and preclinical immunotherapy programs.
Janux Therapeutics (JANX) reported Q3 2025 results. Collaboration revenue reached $10,000 (vs. $439 in Q3 2024), driven by a $10.0 million Merck milestone achieved in August tied to the first collaboration target. R&D expense was $34,629 and G&A was $10,622, leading to a net loss of $24,313, or $0.39 per share.
For the nine months, revenue totaled $10,000, operating expenses were $125,266, and net loss was $81,679. Interest income contributed $33,587 year-to-date. Cash and cash equivalents were $48,389 and short‑term investments were $940,604 as of September 30, supporting total assets of $1,024,766. Net cash used in operating activities was $53,693 for the period. Shares outstanding were 60,123,602 at quarter end; 60,147,807 were outstanding as of November 4, 2025.
The company states it has sufficient capital to fund operations for at least 12 months. Performance obligations under the Merck collaboration were completed as of September 30, 2025, with future milestones recognized only upon occurrence.